Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 27, 2026

Star Equity (STRR) Q3 2025 Earnings Transcript

View original at finance.yahoo.com
Star Equity (STRR) Q3 2025 Earnings Transcript Image source: The Motley Fool. DATE Thursday, November 13, 2025 at 10 a.m…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Star Equity stock is undervalued

    80% confidence

  • RPO market is bouncing along bottom with gradual return to normal attrition

    80% confidence

  • Energy Services growth opportunities are outsized versus larger competitors

    80% confidence

  • 2022 baseline of $100M gross profit and $20M EBITDA (20% margin) is considered mid-cycle normalized for Business Services

    80% confidence

  • Target synergies of $2M annually will be fully realized within 6 months (by mid-2026)

    80% confidence

  • Gyrodyne plans to complete liquidation of real estate assets by end of 2027

    80% confidence

  • Exploring partnership with private equity or growth capital for AI/digital investments in Business Services, with high probability eventually (multiple quarters out)

    80% confidence

  • Jeffrey Eberwein has been buying shares at higher prices than current $9 range

    80% confidence

  • Gyrodyne is trading 50-60% below stated NAV

    80% confidence

  • Target 30% incremental margin at scale for Business Services segment

    80% confidence

  • Building Solutions targets mid-20% gross margin

    80% confidence

  • Corporate costs will reduce from $2.6M/quarter to ~$2M/quarter run rate ($8M annually)

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com